Clinical Trial Update: Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE) [Phase 2]

View source ↗

Summary

Phase 2 trial of RC18 given subcutaneously in systemic lupus erythematosus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• RC18 (RC18)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED